Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ONK Therapeutics

Request full access

Pioneering optimally engineered NK cell therapies to cure patients with cancer

Galway, IrelandFounded 2015Biotech & Life Sciences

About ONK Therapeutics

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Galway, Ireland
Employees
14
Open positions
None listed
Dealroom signal
67.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Cellular, Spinout, Biotech and Pharma, Cell Therapy, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jan 2022 $22M $86M Cormorant Asset Management · Acorn Bioventures · Enterprise Ireland · ALSHC ↗
EARLY VC✓Equity / VC Oct 2020 $8M $32M Seamus Mulligan · Acorn Bioventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ONK Therapeutics website traffic

Latest recorded traffic for ONK Therapeutics is 1.3K monthly website visits, down 55.2% over the last three months. ONK Therapeutics's team declined 6.7% over the past year.

Latest monthly visits1.3K 3-month web change-55.2% 1-year team growth-6.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ONK Therapeutics in the Galway ecosystem

Live from Dealroom

The ONK Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • University of Galway
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States50%
🇮🇪 Ireland50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ONK Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ONK Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.